{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:14Z","timestamp":1790363594104,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the SELECT\u2010AXIS 1 study, adults with active AS and an inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive upadacitinib 15 mg once daily or placebo. At week 14, patients who had been randomized to receive placebo were switched to upadacitinib, and all patients continued in the open\u2010label extension and received upadacitinib up to week 104; interim data up to week 64 are reported herein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 187 patients, 178 completed week 14 on study drug and entered the open\u2010label extension. Similar proportions of patients in either group (continuous upadacitinib or placebo\u2010to\u2010upadacitinib) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40) or Ankylosing Spondylitis Disease Activity Score (ASDAS) showing low disease activity at week 64: \u226570% of patients achieved these end points based on nonresponder imputation (NRI) and \u226581% based on as\u2010observed analyses. Furthermore, \u226534% (NRI) and \u226539% (as\u2010observed analysis) achieved ASDAS showing inactive disease or ASAS showing partial remission at week 64. Mean changes from baseline (week 0) to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib (237.6 patient\u2010years), 618 adverse events (260.1 per 100 patient\u2010years) were reported. No serious infections, major adverse cardiovascular events, venous thromboembolic events, gastrointestinal perforation, or deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.41911","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:06:20Z","timestamp":1625184380000},"page":"70-80","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One\u2010Year Results of a Double\u2010Blind, Placebo\u2010Controlled Study and Open\u2010Label Extension"],"prefix":"10.1002","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[{"name":"Oregon Health &amp; Science University  Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"VIB\u2010UGent Center for Inflammation Research and Ghent University  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae\u2010Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Hanyang University Hospital for Rheumatic Diseases  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ostor","sequence":"additional","affiliation":[{"name":"Cabrini Medical Center and Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Montpellier and Universit\u00e9 de Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Sui","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina D.","family":"Chu","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u2010Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000589"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"e_1_2_8_7_1","unstructured":"Rinvoq (upadacitinib) prescribing information.North Chicago (IL):AbbVie;2019."},{"key":"e_1_2_8_8_1","unstructured":"Xeljanz (tofacitinib) prescribing information.New York (NY):Pfizer Laboratories;2019."},{"key":"e_1_2_8_9_1","unstructured":"Olumiant (baricitinib) prescribing information.Indianapolis (IN):Lilly LLC 2018."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key070"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41584-019-0355-y","article-title":"New positive results for upadacitinib in AS [review]","volume":"16","author":"Onuora S","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"e_1_2_8_14_1","article-title":"Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double\u2010blind, placebo\u2010controlled study [abstract]","volume":"72","author":"Deodhar A","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_19_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38921"},{"key":"e_1_2_8_24_1","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index","volume":"21","author":"Jenkinson TR","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep457"},{"key":"e_1_2_8_28_1","first-page":"S72","article-title":"Psychometric and scaline properties of a new quality of life instrument specific to ankylosing spondylitis [abstract]","volume":"42","author":"Helliwell PS","year":"1999","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38973"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01001-1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2020-eular.6727","article-title":"LB0001 efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non\u2010biologic disease\u2010modifying anti\u2010rheumatic drugs (SELECT\u2010PsA\u20101): a double\u2010blind, randomized controlled phase 3 trial [abstract]","volume":"79","author":"McInnes I","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13650"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1325034"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39670"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/annrheumdis-2019-eular.7509","article-title":"FRI0131 elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib","volume":"78","author":"Queeney K","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_40_1","unstructured":"Cimzia (certolizumab pegol) summary of product characteristics.Bruxelles (Belgium):UCB Pharma 2020."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0930-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1671"},{"issue":"10","key":"e_1_2_8_45_1","article-title":"Exposure\u2010response analyses for upadacitinib efficacy and safety in ankylosing spondylitis\u2013analyses of the SELECT\u2010AXIS I study [abstract]","volume":"71","author":"Ismail M","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"issue":"10","key":"e_1_2_8_47_1","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement [abstract]","volume":"72","author":"Deodhar A","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_48_1","unstructured":"AbbVie sponsor.A study to evaluate efficacy and safety of upadacitinib in adult participants with axial spondyloarthritis (SELECT\u2010AXIS 2). ClinicalTrials.gov identifier: NCT04169373."}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41911","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:18:31Z","timestamp":1759940311000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/art.41911"],"URL":"https:\/\/doi.org\/10.1002\/art.41911","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"2021-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}